Targeted Therapies For The Treatment Of Kidney Cancer, Eric Jonasch, MD

(28:46)

Dr. Eric Jonasch - 2019 KCA Grant Recipient

(6:51)

ESMO22 Highlights: Dr. Jonasch Discusses the COSMIC313 Trial for Kidney Cancer

(1:37)

Frontline Treatment For Renal Cell Carcinoma - Eric Jonasch

(22:8)

What Are The Next Therapies On The Horizon For The Treatment Of Kidney Cancer? Eric Jonasch, MD

(27:11)

Hypoxia Inducible Factors Mediate Immune Evasion of Cancer Cells| Gregg L. Semenza, MD, PhD

(28:38)

Clinical Management of VHL Tumors - Systemic Agents for VHL | Medical Symposium 2024

(1:19:38)

NF-κB Signal Pathway

(11:21)

WKCD 2022 Talking Treatments Webinar

(58:54)

Friday PM Q A Eric Liu, MD Mary Maluccio, MD, MPH, FACS Edward M Wolin, MD Nikolaos Trikolinos, MD

(35:)

The Kidney Cancer Research Program: Transforming Kidney Cancer Research and Treatment

(2:58)

AACR 2011: Stephen J. Chanock, M.D.

(7:12)

Case Presentations

(1:30:56)

NACFC09 - An Interview with Dr. Eric Sorscher

(2:38)

Renal Cell Carcinoma: Past, Present, and Future

(59:55)

#KCRS19: Eric Jonasch, M.D.

(1:38)

Von Hippel-Lindau Disease Management: Expert Insights | Dr. Eric Jonasch | CME Activity

(52:51)

MyVHL and Dr. Eric Jonasch - The VHL Alliance

(34)

VHL and HIF-2alpha Inhibitors: A Conversation with Dr Eric Jonasch

(30:12)

#KCRS20 \

(43)

FDA Approval of Belzutifan | Eric Jonasch, MD

(29:8)

2020 International VHL Medical/Research Symposium: Eric Jonasch, MD

(28:5)

Dr Eric Jonasch - ASCO GU 2017

(1:19)

Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in

(1:42)

Dr. Eric Jonasch - World Kidney Cancer Day 2018

(22)

Dr Jonasch on the Preliminary Efficacy of NKT-2152 in Advanced ccRCC

(1:4)

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

(1:17)

Brain Metastases and Kidney Cancer: Insights from Dr. Eric Jonasch (MD Anderson Cancer Center)

(2:20)

Eric Jonasch, MD, recognizes interesting clinical presentations regarding RCC management at ASCO20

(2:53)

Eric Jonasch, MD, on the 4 year Checkmate-214 follow up investigating nivolumab + ipilimumab

(47)